1. Home
  2. BTG vs CYTK Comparison

BTG vs CYTK Comparison

Compare BTG & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTG
  • CYTK
  • Stock Information
  • Founded
  • BTG 2006
  • CYTK 1997
  • Country
  • BTG Canada
  • CYTK United States
  • Employees
  • BTG N/A
  • CYTK N/A
  • Industry
  • BTG Precious Metals
  • CYTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • BTG Basic Materials
  • CYTK Health Care
  • Exchange
  • BTG Nasdaq
  • CYTK Nasdaq
  • Market Cap
  • BTG 4.9B
  • CYTK 4.6B
  • IPO Year
  • BTG N/A
  • CYTK 2004
  • Fundamental
  • Price
  • BTG $4.12
  • CYTK $35.39
  • Analyst Decision
  • BTG Buy
  • CYTK Buy
  • Analyst Count
  • BTG 3
  • CYTK 13
  • Target Price
  • BTG $4.25
  • CYTK $71.58
  • AVG Volume (30 Days)
  • BTG 29.5M
  • CYTK 1.7M
  • Earning Date
  • BTG 08-07-2025
  • CYTK 08-07-2025
  • Dividend Yield
  • BTG 2.42%
  • CYTK N/A
  • EPS Growth
  • BTG N/A
  • CYTK N/A
  • EPS
  • BTG N/A
  • CYTK N/A
  • Revenue
  • BTG $2,172,330,000.00
  • CYTK $85,738,000.00
  • Revenue This Year
  • BTG $66.93
  • CYTK $330.96
  • Revenue Next Year
  • BTG $6.87
  • CYTK $73.41
  • P/E Ratio
  • BTG N/A
  • CYTK N/A
  • Revenue Growth
  • BTG 11.75
  • CYTK 2635.74
  • 52 Week Low
  • BTG $2.20
  • CYTK $29.31
  • 52 Week High
  • BTG $4.14
  • CYTK $59.39
  • Technical
  • Relative Strength Index (RSI)
  • BTG 65.54
  • CYTK 49.60
  • Support Level
  • BTG $3.72
  • CYTK $36.89
  • Resistance Level
  • BTG $4.10
  • CYTK $39.92
  • Average True Range (ATR)
  • BTG 0.12
  • CYTK 1.78
  • MACD
  • BTG 0.02
  • CYTK -0.06
  • Stochastic Oscillator
  • BTG 91.67
  • CYTK 54.96

About BTG B2Gold Corp Common shares (Canada)

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: